BCRX
BioCryst Pharmaceuticals Inc
8.30$
-1.3%
vs. previous close
Closing price · As of: Oct 8, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 16 | Q4 16 | Q1 17 | Q2 17 | Q3 17 | Q4 17 | Q1 18 | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 1.8% | 27.3% | 3.1% | 0.7% | 14.3% | 3.3% | 3.5% | 1.9% | 1.2% | 2.6% | 25.2% | 1.8% | 1.0% | 6.5% | 1.4% | 957.8% | 25.0% | 2.0% | 31.1% | 0.7% | 1.5% | 0.9% | 0.5% | 0.4% | 4.8% | 3.1% | 1.4% | 1.2% | 1.3% | 1.8% | 1.4% | 1.6% | 2.8% | 4.7% | 3.1% | 1.7% | 1.6% | 2.4% | 449.5% | 1.8% | 76.5% | |
| 98.2% | 72.7% | 96.9% | 99.3% | 85.7% | 96.7% | 96.5% | 98.1% | 98.8% | 97.4% | 74.8% | 98.2% | 99.0% | 93.5% | 98.6% | 100.0% | 75.0% | 98.0% | 68.9% | 99.3% | 98.5% | 99.1% | 99.5% | 99.6% | 95.2% | 96.9% | 98.6% | 98.8% | 98.7% | 98.2% | 98.6% | 98.4% | 97.2% | 95.3% | 96.9% | 98.3% | 98.4% | 97.6% | -349.5% | 98.2% | 23.5% | |
| 181.7% | 135.3% | 177.7% | 508.5% | 199.9% | 435.1% | 463.8% | 168.2% | 1,513.5% | 858.6% | 467.0% | 1,911.7% | 1,415.2% | 67.4% | 619.3% | 957.8% | 495.7% | 880.3% | 222.7% | 105.8% | 121.9% | 134.7% | 130.9% | 94.6% | 69.6% | 92.0% | 70.4% | 62.1% | 54.0% | 75.0% | 50.1% | 34.4% | 35.1% | 37.6% | 25.6% | 26.6% | 27.8% | 10.1% | 38.6% | 23.8% | 21.0% | |
| 35.5% | 28.5% | 32.4% | 91.4% | 38.2% | 120.8% | 191.4% | 76.0% | 544.9% | 164.5% | 106.0% | 598.0% | 661.1% | 26.4% | 328.9% | 483.6% | 281.8% | 1,168.9% | 108.7% | 49.1% | 81.7% | 72.9% | 60.7% | 51.8% | 48.7% | 58.9% | 63.7% | 57.8% | 58.4% | 53.5% | 64.0% | 56.0% | 55.6% | 61.2% | 56.7% | 53.5% | 52.1% | 23.6% | 60.5% | 29.3% | 35.9% | |
| 217.2% | 163.9% | 210.1% | 600.0% | 238.0% | 555.8% | 655.2% | 244.1% | 2,058.4% | 1,023.1% | 573.0% | 2,509.7% | 2,076.3% | 93.8% | 948.2% | 1,441.3% | 777.5% | 1,402.9% | 338.5% | 158.5% | 207.3% | 209.8% | 199.6% | 152.6% | 118.2% | 155.1% | 140.0% | 123.9% | 112.4% | 143.9% | 114.3% | 90.4% | 90.7% | 98.8% | 82.3% | 80.1% | 79.9% | 33.6% | 99.0% | 53.1% | 56.9% | |
| -119.0% | -91.1% | -113.2% | -500.7% | -152.4% | -459.2% | -558.7% | -146.1% | -1,959.6% | -925.7% | -498.2% | -2,411.5% | -1,977.4% | -0.3% | -849.6% | -1,341.3% | -702.5% | -1,304.9% | -269.6% | -59.2% | -108.8% | -110.6% | -100.1% | -53.0% | -23.0% | -58.2% | -41.3% | -25.1% | -13.7% | -45.7% | -15.6% | 8.0% | 6.6% | -3.4% | 14.6% | 18.2% | 18.6% | 64.0% | -448.6% | 45.1% | -33.3% | |
| 18.9% | 23.7% | 22.3% | 67.6% | 24.4% | 57.4% | 55.9% | 17.6% | 161.3% | 88.5% | 46.3% | 209.6% | 171.5% | 7.8% | 63.2% | 101.6% | 53.1% | 139.7% | 67.7% | 27.0% | 34.4% | 39.8% | 47.7% | 36.7% | 32.7% | 33.3% | 39.8% | 35.1% | 31.5% | 26.3% | 26.4% | 22.6% | 21.2% | 18.6% | 16.1% | 13.2% | 12.3% | 3.5% | 12.6% | 9.9% | 8.0% | |
| -148.5% | -50.1% | -150.7% | -544.9% | -172.8% | -502.4% | -648.3% | -147.6% | -2,035.6% | -1,005.2% | -527.5% | -2,598.7% | -2,117.9% | -6.6% | -779.6% | -1,344.7% | -755.7% | -1,506.3% | -337.3% | -86.5% | -143.4% | -32.9% | -148.1% | -88.5% | -54.1% | -89.8% | -76.6% | -90.4% | -41.3% | -67.6% | -37.7% | -11.4% | -11.5% | -19.8% | 0.5% | 4.0% | 7.6% | 61.0% | -460.8% | 36.4% | -40.5% | |
| 16.6% | 21.8% | 20.4% | 62.0% | 22.4% | 52.7% | 55.9% | 16.0% | 147.9% | 81.2% | 43.3% | 197.1% | 161.2% | 7.3% | 58.7% | 95.3% | 50.3% | 135.2% | 67.7% | 26.6% | 33.9% | 4.8% | 0.6% | 1.3% | 2.0% | 0.1% | 1.0% | 0.9% | 0.4% | -1.5% | 0.4% | 0.2% | 0.5% | 0.6% | 0.5% | 0.9% | -0.5% | 0.5% | 0.6% | 0.5% | 0.4% | |
| -148.5% | -50.1% | -150.7% | -544.9% | -172.8% | -502.4% | -648.3% | -147.6% | -2,035.6% | -1,005.2% | -527.5% | -2,598.7% | -2,117.9% | -6.6% | -779.6% | -1,344.7% | -755.7% | -1,506.3% | -337.3% | -86.5% | -143.4% | -37.7% | -148.6% | -89.8% | -56.1% | -89.9% | -77.5% | -91.3% | -41.7% | -66.1% | -38.1% | -11.6% | -12.0% | -20.4% | 0.0% | 3.1% | 8.1% | 60.5% | -461.5% | 35.9% | -40.9% | |
| -127.4% | -24.5% | -126.6% | -471.8% | -146.3% | -440.4% | -587.8% | -128.5% | -1,860.8% | -909.5% | -478.2% | -2,376.6% | -1,936.1% | 1.6% | -711.9% | -1,236.7% | -699.9% | -1,362.2% | -268.6% | -59.1% | -108.4% | 7.3% | -99.7% | -51.3% | -20.9% | -56.1% | -36.1% | -54.9% | -9.3% | -40.9% | -11.0% | 11.5% | 10.0% | -0.9% | 16.9% | 17.4% | 20.2% | 65.5% | -447.5% | 45.2% | -32.2% |
LTM = last twelve months (sum of the four most recent quarters).
Showing the most recent 40 periods — older statements are on file for this stock.
Data as of: October 8, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.